Investor relations
A two-phase, asset-backed build-out of a globally compliant herbal API platform — open to equity, debt or hybrid partners.
Why Chemicraft
INR 195 Cr
Total project size (approx. USD 21.7 million), including pre-production OPEX.
2 phases
Phase 1: Herbal APIs & Nicotine. Phase 2: Vitamin D3 & Nutraceuticals.
~80% export
Export-led revenue mix targeting regulated markets.
5–7 yrs
Indicative investor horizon for capital events.
Compliance-led, premium-margin, scalable
- First-mover niche: few Indian manufacturers combine nicotine, Vitamin D3 and botanical actives under multi-product GMP.
- Technology edge: TOR distillation, supercritical CO2 extraction, advanced analytics.
- Regulatory ready: drug licences in place; WHO-GMP and USFDA-DMF on the roadmap.
- Sticky revenue: long qualification cycles and multi-year supply contracts.
- Policy tailwind: the Haryana Pharmaceutical & Medical Devices Manufacturing Policy 2026 offers capital, operating and employment support.
- Experienced promoters: 100+ years of combined pharma experience.
Structured to fit different investors
Phase 1 (INR 100 Cr CAPEX) funds Herbal APIs and Nicotine; Phase 2 (INR 60 Cr CAPEX) funds Vitamin D3 and nutraceuticals, with additional pre-production OPEX.
Execution roadmap
Incorporation, registrations & drug trade licences
Company incorporated in Haryana; GST, IEC, UDYAM, LEI and two drug licences secured; 15-acre site finalised.
Site & regulatory setup
DPR sign-off, Consent to Establish, land finalisation, investment close.
Engineering, construction & commissioning
Design, civil works, equipment, IQ/OQ/PQ.
Trial production & GMP validation
Batch testing and WHO-GMP audit preparation.
Phase 1 commercial launch
First API production and revenue.
Phase 2 build and commercial launch
Vitamin D3 and nutraceutical actives.
Important information
This website is provided for general information and does not constitute an offer or solicitation to invest. Statements on plans, projections, timelines and expectations are forward-looking and involve risks and uncertainties, including regulatory changes, market conditions, competition, raw-material availability, exchange rates and execution risk; actual results may differ materially. Projections are management estimates and not guarantees. Recipients should conduct independent due diligence before making any investment decision.
Frequently asked questions
How large is the Chemicraft project?
The total project size is INR 195 Crore (approximately USD 21.7 million), delivered in two phases: Phase 1 for herbal APIs and nicotine and Phase 2 for Vitamin D3 and nutraceuticals.
What forms of investment are welcome?
The capital plan is structured to accommodate equity, debt or hybrid investment partners.
How can I access detailed financials?
Detailed financial information, including capital structure, valuation, projections and returns, is shared under a Non-Disclosure Agreement with qualified investors and financing institutions. Use the contact form to request the investor pack.
Discuss the opportunity
Qualified investors and financing institutions can request the confidential information memorandum.